vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes

Reuters
20 May
vTv <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes

vTv Therapeutics Inc. has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10